Relebactam is a diazabicyclooctane beta-lactamase inhibitor, structurally similar to avibactam, and serves as an active pharmaceutical ingredient used in combination with imipenem and cilastatin. It features a piperidine ring that imparts a positive charge, reducing bacterial export, and was approved by the FDA in 2019 as part of the Recarbrio® combination product for treating complicated urinary tract infections, pyelonephritis, and complicated intra-abdominal infections in adults.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 1174018-99-5
Relebactam monohydrate
pharmaceutical raw material
Clavulanate potassium
pharmaceutical raw material
Cefditoren pivoxil
pharmaceutical raw material
Calcium dobesilate monohydrate
pharmaceutical raw material
Desethanol dipyridamole
pharmaceutical raw material
Desosaminylazithromycin
pharmaceutical raw material
1,1-Dimethylethyl 4-[[[(1R,2S,5R)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl]amino]-1-piperidinecarboxylate
research compound
[(2S,5R)-7-oxo-2-(piperidin-4-ylcarbamoyl)-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate
SMOBCLHAZXOKDQ-ZJUUUORDSA-N
C1C[C@H](N2C[C@@H]1N(C2=O)OS(=O)(=O)O)C(=O)NC3CCNCC3